Starpharma Holdings (ASX:SPL) Institutional Ownership: 12.35% (As of Jul. 08, 2026)


ASX:SPL Starpharma Holdings Ltd ASX:SPL
53 GF Score
Price A$0.71
GF Value A$0.44
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Starpharma Holdings Institutional Ownership?

Starpharma Holdings ASX:SPL -0.70% 53 Institutional Ownership is 12.35% as of Jul. 08, 2026. GuruFocus rates ASX:SPL with a GF Score™ of 53/100 and a GF Value™ of A$0.44 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Starpharma Holdings's institutional ownership is 12.35%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Starpharma Holdings's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Starpharma Holdings's Float Percentage Of Total Shares Outstanding is 0.00%.

Starpharma Holdings Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Starpharma Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starpharma Holdings Institutional Ownership Chart

Starpharma Holdings Historical Data

The historical data trend for Starpharma Holdings can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 11.69 11.88 11.86 11.77 12.27 12.24 12.12 12.35 12.35 12.35
ASX:SPL
53GF Score
Starpharma Holdings Ltd ASX:SPL
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starpharma Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 12.35% mean?
Starpharma Holdings (ASX:SPL) has a Institutional Ownership of 12.35% as of Jul. 08, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Starpharma Holdings and its competitors.
Is Starpharma Holdings' Institutional Ownership too high?
Starpharma Holdings' current Institutional Ownership is 12.35%. Overall, Starpharma Holdings has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Institutional Ownership compare to VRTX and REGN?
Starpharma Holdings' Institutional Ownership of 12.35% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Starpharma Holdings and its competitors. Starpharma Holdings's current Institutional Ownership is 12.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.44, compared to a current price of A$0.71 — trading 61.4% above its estimated fair value. The current Institutional Ownership is 12.35%. Starpharma Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Institutional Ownership is 12.35% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?

Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued. The current stock price of A$0.71 is trading 61.4% above its estimated GF Value™ of A$0.44. GuruFocus considers Starpharma Holdings to be Significantly Overvalued.

Key valuation signals for ASX:SPL:

  • Institutional Ownership: 12.35%
  • GF Value™: A$0.44 vs. price of A$0.71 (61.4% above fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Starpharma Holdings Business Description

Address 4-6 Southampton Crescent, Abbotsford, Melbourne, VIC, AUS, 3067
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
53GF Score

Get the complete analysis for ASX:SPL

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.71
Price
A$0.44
GF Value